MAPT and frontotemporal dementia: This study might indicate whether targeting tau acetylation has therapeutic potential in FTD; however, the brain penetration of salsalate is limited (<3%) and therefore more potent brain-penetrating inhibitors of tau acetylation might be needed to conclusively test this hypothesis.